Scrip’s Rough Guide To Targeted Protein Degradation

Drugging The Undruggable

By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. Scrip takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.  

Ubiquitinin
Ligase enzyme tags protein for degradation by attaching a ubiquitin molecule • Source: Alamy

Targeted protein degradation, or TPD, has been steadily gaining attention in recent years as a highly promising new drug development strategy that has already attracted significant investment and big pharma attention.

With observers eagerly awaiting early clinical data for a range of novel TPD candidates, Scrip explains how these products work,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Lilly’s Muscle Builder Looks Strong In GLP-1 Obesity Combo

 

Bimagrumab added to Wegovy increased weight loss and preserved muscle mass, but analysts want to see more safety and efficacy results from a combination with Zepbound.

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

 

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Saudi Arabia Plans Advanced Manufacturing Campus Under Biotech Drive

 
• By 

A partnership with Germfree Laboratories will bring a new facility to boost Saudi Arabia’s biotech sector as the world’s largest oil exporter tries to establish itself as a global biotech hub by 2040.